Spyre Therapeutics (SYRE) Return on Capital Employed Growth (5y) (2021 - 2026)
Spyre Therapeutics (SYRE) Return on Capital Employed Growth (5y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Spyre Therapeutics | 259.59 Mn | 259.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,253.00 |
| Dec 31, 2025 | 2,133.00 |
| Sep 30, 2025 | 884.00 |
| Jun 30, 2025 | 3,719.00 |
| Mar 31, 2025 | 10,238.00 |
| Dec 31, 2024 | 6,436.00 |
| Sep 30, 2024 | 2,686.00 |
| Jun 30, 2024 | 2,251.00 |
| Mar 31, 2024 | -1,285.00 |
| Dec 31, 2023 | -2,915.00 |
| Sep 30, 2023 | -6,529.00 |
| Jun 30, 2023 | 31,192.00 |
| Mar 31, 2023 | -9,826.00 |
| Dec 31, 2022 | -7,455.00 |
| Sep 30, 2022 | -6,054.00 |
| Jun 30, 2022 | -6,914.00 |
| Mar 31, 2022 | -5,026.00 |
| Dec 31, 2021 | -3,268.00 |
| Sep 30, 2021 | -2,907.00 |
| Jun 30, 2021 | -1,593.00 |